Total Payments
$44,527
2023 Payments
$28.64
Companies
51
Transactions
663
Medicare Patients
2,275
Medicare Billing
$343,700
Payment Breakdown by Category
Other$27,469 (61.7%)
Food & Beverage$10,192 (22.9%)
Travel$4,495 (10.1%)
Research$2,122 (4.8%)
Education$217.73 (0.5%)
Gifts$30.95 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,470 | 40 | 61.7% |
| Food and Beverage | $10,192 | 574 | 22.9% |
| Travel and Lodging | $4,495 | 23 | 10.1% |
| Unspecified | $2,122 | 14 | 4.8% |
| Education | $217.73 | 8 | 0.5% |
| Gift | $30.95 | 4 | 0.1% |
Payments by Type
General
$42,405
649 transactions
Research
$2,122
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $16,840 | 31 | $0 (2023) |
| Allergan, Inc. | $8,696 | 37 | $0 (2021) |
| Biogen, Inc. | $3,130 | 93 | $0 (2020) |
| Alexion Pharmaceuticals, Inc. | $2,971 | 10 | $0 (2020) |
| US WorldMeds, LLC | $2,791 | 20 | $0 (2019) |
| EISAI INC. | $1,395 | 21 | $0 (2019) |
| Roche TCRC, Inc. | $1,363 | 4 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $790.18 | 66 | $0 (2019) |
| Medtronic USA, Inc. | $662.83 | 6 | $0 (2019) |
| EMD Serono, Inc. | $655.76 | 53 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $28.64 | 1 | ABBVIE INC. ($28.64) |
| 2022 | $7,398 | 10 | ABBVIE INC. ($7,398) |
| 2021 | $11,143 | 20 | AbbVie Inc. ($9,393) |
| 2020 | $5,455 | 18 | Allergan, Inc. ($5,249) |
| 2019 | $7,488 | 201 | Alexion Pharmaceuticals, Inc. ($2,863) |
| 2018 | $8,348 | 193 | US WorldMeds, LLC ($2,495) |
| 2017 | $4,666 | 220 | Allergan Inc. ($1,462) |
All Payment Transactions
663 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $28.64 | General |
| Category: NEUROSCIENCE | ||||||
| 12/20/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $8.33 | General |
| Category: NEUROSCIENCE | ||||||
| 05/11/2022 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/11/2022 | ABBVIE INC. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $5.85 | General |
| Category: NEUROSCIENCE | ||||||
| 04/13/2022 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/13/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $124.10 | General |
| Category: NEUROSCIENCE | ||||||
| 04/13/2022 | ABBVIE INC. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $21.65 | General |
| Category: NEUROSCIENCE | ||||||
| 03/30/2022 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/18/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $6.74 | General |
| Category: NEUROSCIENCE | ||||||
| 02/22/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: NEUROSCIENCE | ||||||
| 02/18/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $8.09 | General |
| Category: NEUROSCIENCE | ||||||
| 12/09/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $4.66 | General |
| Category: NEUROSCIENCE | ||||||
| 11/30/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $6.70 | General |
| Category: NEUROSCIENCE | ||||||
| 11/03/2021 | AbbVie Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/03/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.71 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2021 | AbbVie Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,750.00 | General |
| Category: NEUROSCIENCE | ||||||
| 09/02/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $2.33 | General |
| Category: NEUROSCIENCE | ||||||
| 08/13/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $3.10 | General |
| Category: NEUROSCIENCE | ||||||
| 08/06/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $2.68 | General |
| Category: NEUROSCIENCE | ||||||
| 07/14/2021 | AbbVie Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/14/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $111.25 | General |
| Category: NEUROSCIENCE | ||||||
| 07/14/2021 | AbbVie Inc. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $15.68 | General |
| Category: NEUROSCIENCE | ||||||
| 05/26/2021 | AbbVie Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/26/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Biogen, Inc. | $2,122 | 14 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 531 | 678 | $250,703 | $64,928 |
| 2022 | 5 | 572 | 740 | $275,465 | $71,907 |
| 2021 | 7 | 569 | 6,675 | $369,890 | $105,938 |
| 2020 | 9 | 603 | 7,929 | $364,830 | $100,926 |
Total Patients
2,275
Total Services
16,022
Medicare Billing
$343,700
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 305 | 432 | $162,000 | $41,980 | 25.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 81 | 81 | $46,575 | $10,261 | 22.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 92 | 112 | $28,560 | $7,622 | 26.7% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2023 | 53 | 53 | $13,568 | $5,065 | 37.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 289 | 432 | $162,000 | $43,306 | 26.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 109 | 109 | $62,675 | $14,103 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 107 | 131 | $33,405 | $8,737 | 26.2% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2022 | 45 | 45 | $11,520 | $4,374 | 38.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 22 | 23 | $5,865 | $1,388 | 23.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 293 | 486 | $182,250 | $48,728 | 26.7% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 12 | 5,910 | $82,740 | $28,674 | 34.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 109 | 109 | $62,675 | $14,466 | 23.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 75 | 86 | $21,930 | $6,512 | 29.7% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Facility | 2021 | 45 | 45 | $11,520 | $4,598 | 39.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 17 | 21 | $5,355 | $1,599 | 29.9% |
| G0425 | Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth | Facility | 2021 | 18 | 18 | $3,420 | $1,362 | 39.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 13 | 7,200 | $100,800 | $34,913 | 34.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 241 | 360 | $135,025 | $31,331 | 23.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 114 | 114 | $65,550 | $14,526 | 22.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 100 | 114 | $19,335 | $7,160 | 37.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 41 | 42 | $20,790 | $4,636 | 22.3% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Facility | 2020 | 40 | 40 | $10,240 | $4,173 | 40.8% |
| G0425 | Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth | Facility | 2020 | 22 | 22 | $4,180 | $1,681 | 40.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 19 | 23 | $5,865 | $1,289 | 22.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 13 | 14 | $3,045 | $1,217 | 40.0% |
About Dr. Srinath Kadimi, M.D
Dr. Srinath Kadimi, M.D is a Neurology healthcare provider based in Fairfield, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730144734.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Srinath Kadimi, M.D has received a total of $44,527 in payments from pharmaceutical and medical device companies, with $28.64 received in 2023. These payments were reported across 663 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($27,470).
As a Medicare-enrolled provider, Kadimi has provided services to 2,275 Medicare beneficiaries, totaling 16,022 services with total Medicare billing of $343,700. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurology
- Location Fairfield, CT
- Active Since 04/20/2006
- Last Updated 12/18/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1730144734
Products in Payments
- UBRELVY (Drug) $23,738
- APOKYN (Drug) $2,727
- Non-Covered Product (Drug) $1,363
- NAMZARIC (Drug) $1,258
- ACTIVA (Device) $662.83
- TECFIDERA (Drug) $576.15
- Rebif (Biological) $479.10
- XARELTO (Drug) $387.80
- TYSABRI (Biological) $355.05
- Briviact (Drug) $326.34
- AUSTEDO (Drug) $274.77
- GILENYA (Drug) $271.79
- TROKENDI XR (Drug) $246.46
- APTIOM (Drug) $244.15
- AMPYRA (Drug) $241.31
- COPAXONE (Drug) $227.02
- SOLIRIS (Drug) $222.60
- ONFI (Drug) $196.13
- AJOVY (Drug) $188.44
- Mavenclad (Biological) $176.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Fairfield
Peter Mcallister, M.d, M.D
Neurology — Payments: $2.3M
Neurology $2.3M
P. Christopher Gottschalk, M.d, M.D
Neurology — Payments: $400,249
Neurology $400,249
Jeffrey Gross, M.d, M.D
Neurology — Payments: $191,862
Neurology $191,862
Dr. Nicholas Blondin, M.d, M.D
Neurology — Payments: $144,704
Neurology $144,704
Dario Zagar, M.d, M.D
Neurology — Payments: $19,926
Neurology $19,926
Mrs. Ruby Ali, M.d, M.D
Neurology — Payments: $18,050
Neurology $18,050